Gaithersburg-based Emergent BioSolutions Inc. is adding a $31 million contract from the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority to its ongoing work developing a next-generation anthrax vaccine.
The BARDA contract is for NuThrax, a vaccine that requires fewer doses, has a higher immune response and has no need for refrigeration.
{iframe}http://www.bizjournals.com/washington/news/2015/03/24/emergent-gets-31m-contract-for-next-generation.html{/iframe}